13F Holdings
中文EN

ARTV Artiva Biotherapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1817241 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-23.9%
TTM EPS YoY-129.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-43.6%
ROA-39.9%
ROIC (approx.)-45.8%
Asset turnover—

Leverage & solvency

Liabilities / assets6.5%
Debt / equity0.00x
Current ratio19.88x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.86x
Accruals ratio-5.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31
Income statement
Revenue$0$251,000$33.49M
R&D expense$69.54M$50.33M$50.25M
SG&A expense$20.27M$17.20M$13.91M
Operating income-$89.81M-$67.28M-$30.67M
Pretax income$83.90M$65.40M-$28.65M
Income tax$0$0$72,000
Net income-$83.86M-$65.37M-$28.72M
EBITDA-$87.21M-$64.85M-$28.41M
EPS (basic)-3.43-5.81-35.78
EPS (diluted)-3.43-5.81-35.78
Weighted avg. shares (diluted)24.44M11.26M802,747
Balance sheet
Cash & equivalents$26.70M$40.49M$53.76M
Short-term investments$81.31M$145.19M$23.47M
Receivables—$0$1.03M
Current assets$112.67M$188.63M$79.82M
PP&E, net$6.62M$6.37M$8.10M
Total assets$130.94M$209.58M$105.11M
Current liabilities$13.09M$12.25M$12.23M
Total liabilities$20.97M$22.94M$50.72M
Shareholders' equity$109.97M$186.64M-$162.01M
Cash flow statement
Operating cash flow-$76.75M-$55.03M-$47.43M
Capital expenditure$2.59M$642,000$3.26M
Free cash flow-$79.34M-$55.67M-$50.69M
Investing cash flow$63.41M-$120.46M-$25.98M
Financing cash flow$9,000$162.23M$24.39M
Depreciation & amortization$2.60M$2.43M$2.27M
Stock-based compensation$6.82M$6.98M$7.05M

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.